Ardelyx, Inc. (ARDX) stock
ARDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3059% below fair value
$3.09−0.03 (-0.96%)
Close on Nov 13, 2026Market cap $769.99MP/E –Yield –
Ardelyx r&d expenses
Research and development expenses are spending on new products and technology.
Ardelyx's R&D Expenses for the twelve months ending Jun 30, 2026 was $87.21M, up 46.4% year over year. For fiscal 2025 it was $71.53M, up 36.7% from the year before. Over ten years it grew 6.0% a year on average. The highest annual figure on record is $94.16M in fiscal 2016.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $71.53M | +36.7% |
| FY2024 | Dec 31, 2024 | $52.32M | +47.2% |
| FY2023 | Dec 31, 2023 | $35.54M | +1.0% |
| FY2022 | Dec 31, 2022 | $35.20M | -61.4% |
| FY2021 | Dec 31, 2021 | $91.14M | +40.1% |
| FY2020 | Dec 31, 2020 | $65.05M | -9.2% |
| FY2019 | Dec 31, 2019 | $71.68M | +3.3% |
| FY2018 | Dec 31, 2018 | $69.37M | -8.1% |
| FY2017 | Dec 31, 2017 | $75.48M | -19.8% |
| FY2016 | Dec 31, 2016 | $94.16M | +136.1% |
| FY2015 | Dec 31, 2015 | $39.89M | +54.0% |
| FY2014 | Dec 31, 2014 | $25.90M | -7.8% |
| FY2013 | Dec 31, 2013 | $28.09M | +175.9% |
| FY2012 | Dec 31, 2012 | $10.18M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $26.10M | +66.6% |
| Q1 FY2026 | Mar 31, 2026 | $20.19M | +35.1% |
| Q4 FY2025 | Dec 31, 2025 | $22.86M | +67.2% |
| Q3 FY2025 | Sep 30, 2025 | $18.07M | +18.0% |
| Q2 FY2025 | Jun 30, 2025 | $15.67M | +22.8% |
| Q1 FY2025 | Mar 31, 2025 | $14.94M | +41.2% |
| Q4 FY2024 | Dec 31, 2024 | $13.67M | +43.5% |
| Q3 FY2024 | Sep 30, 2024 | $15.31M | +77.3% |
| Q2 FY2024 | Jun 30, 2024 | $12.76M | +54.1% |
| Q1 FY2024 | Mar 31, 2024 | $10.58M | +16.3% |
| Q4 FY2023 | Dec 31, 2023 | $9.52M | +4.2% |
| Q3 FY2023 | Sep 30, 2023 | $8.64M | +15.7% |
| Q2 FY2023 | Jun 30, 2023 | $8.28M | -15.0% |
| Q1 FY2023 | Mar 31, 2023 | $9.09M | +2.7% |
| Q4 FY2022 | Dec 31, 2022 | $9.14M | -56.4% |
| Q3 FY2022 | Sep 30, 2022 | $7.47M | -68.5% |
| Q2 FY2022 | Jun 30, 2022 | $9.74M | -62.6% |
| Q1 FY2022 | Mar 31, 2022 | $8.85M | -56.7% |
| Q4 FY2021 | Dec 31, 2021 | $20.97M | +15.8% |
| Q3 FY2021 | Sep 30, 2021 | $23.70M | +93.6% |
| Q2 FY2021 | Jun 30, 2021 | $26.02M | +37.9% |
| Q1 FY2021 | Mar 31, 2021 | $20.46M | +29.1% |
| Q4 FY2020 | Dec 31, 2020 | $18.11M | +27.1% |
| Q3 FY2020 | Sep 30, 2020 | $12.24M | -30.4% |
| Q2 FY2020 | Jun 30, 2020 | $18.86M | -3.1% |
| Q1 FY2020 | Mar 31, 2020 | $15.84M | -22.3% |
| Q4 FY2019 | Dec 31, 2019 | $14.24M | -35.4% |
| Q3 FY2019 | Sep 30, 2019 | $17.58M | -2.0% |
| Q2 FY2019 | Jun 30, 2019 | $19.48M | +21.4% |
| Q1 FY2019 | Mar 31, 2019 | $20.38M | +52.7% |
| Q4 FY2018 | Dec 31, 2018 | $22.04M | +28.4% |
| Q3 FY2018 | Sep 30, 2018 | $17.94M | +16.8% |
| Q2 FY2018 | Jun 30, 2018 | $16.05M | -22.0% |
| Q1 FY2018 | Mar 31, 2018 | $13.35M | -40.4% |
| Q4 FY2017 | Dec 31, 2017 | $17.16M | -34.5% |
| Q3 FY2017 | Sep 30, 2017 | $15.37M | -38.2% |
| Q2 FY2017 | Jun 30, 2017 | $20.57M | – |
| Q1 FY2017 | Mar 31, 2017 | $22.39M | – |
| Q4 FY2016 | Dec 31, 2016 | $26.21M | – |
| Q3 FY2016 | Sep 30, 2016 | $24.86M | – |
See a number that looks wrong?